News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MacroGenics, Inc. (MGNX) DART Therapeutic Selected By Boehringer Ingelheim Corporation As A Bi-Specific Pre-Clinical Development Candidate


11/11/2013 11:57:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that Boehringer Ingelheim has nominated a bi-specific antibody therapeutic candidate generated by MacroGenics' Dual-Affinity Re-Targeting (DARTâ„¢) technology for pre-clinical development. This will trigger a $5 million milestone payment to MacroGenics under the companies' October 2010 agreement to discover, develop and commercialize up to 10 DART-based therapeutics, which may span multiple therapeutic areas. In addition, Boehringer Ingelheim will pay a research maintenance payment of $4 million to MacroGenics in the fourth quarter of 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES